Functional imaging of the heart and brain
Lead Research Organisation:
University of Oxford
Department Name: Clinical Neurosciences
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- University of Oxford, United Kingdom (Collaboration, Lead Research Organisation)
- UK Biobank, United Kingdom (Collaboration)
- University of Warwick, United Kingdom (Collaboration)
- John Radcliffe Hospital, United Kingdom (Collaboration)
- Maastricht University (UM) (Collaboration)
- Julich Research Centre, Germany (Collaboration)
- Newcastle University, United Kingdom (Collaboration)
- Medical Research Council (Collaboration)
- GE Healthcare Limited, Cardiff (Collaboration)
- McGill University, Canada (Collaboration)
- University of Siena (Collaboration)
- Imanova (Collaboration)
- University of Manchester, Manchester, United Kingdom (Collaboration)
Publications
Arthurs OJ
(2004)
Attention differentially modulates the coupling of fMRI BOLD and evoked potential signal amplitudes in the human somatosensory cortex.
in Experimental brain research
Bosnell R
(2008)
Reproducibility of fMRI in the clinical setting: implications for trial designs.
in NeuroImage
Cader S
(2006)
Reduced brain functional reserve and altered functional connectivity in patients with multiple sclerosis.
in Brain : a journal of neurology
Ciccarelli O
(2006)
Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis.
in Journal of neurology
Crofts JJ
(2011)
Network analysis detects changes in the contralesional hemisphere following stroke.
in NeuroImage
De Luca M
(2005)
Blood oxygenation level dependent contrast resting state networks are relevant to functional activity in the neocortical sensorimotor system.
in Experimental brain research
Enzinger C
(2009)
Brain activity changes associated with treadmill training after stroke.
in Stroke
Filippini N
(2011)
Differential effects of the APOE genotype on brain function across the lifespan.
in NeuroImage
Floyer-Lea A
(2004)
Changing brain networks for visuomotor control with increased movement automaticity.
in Journal of neurophysiology
| Description | Engagement with MHRA for establishing an expert or "superuser" group to help the UK community best respond to MHRA guidelines for PET |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Description | Public consultation roll out of participant involvement in research- MRC/WT sponsorted |
| Geographic Reach | National |
| Policy Influence Type | Participation in a advisory committee |
| Impact | Changes in perception of clinical trials |
| Title | Evaluation of IL2 as a fluorinated PET tracer |
| Description | IL2 can be a used as a molecular probe for T-cells in humans. The work refined and evaluated a method for preparation that had been described by European collaborators. Unfortunately, we proved it to degrade the molecule and hence are developing new approaches. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | The work has informed R and D in GSK, which had been intending to apply the F-IL2 tracer |
| Title | Genotypic modelling of TSPO PET |
| Description | Defined how to use common polymorphism to better model an inflammatory marker |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | Genotyping now routinely incorporated into research practice |
| Title | Implementation of radiotracers for research use |
| Description | A number of radiotracers were newly implemented in the UK Imanova centre including rolipram, PBR28, PBR111 and additional work was done to make PE2I avaliable. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2011 |
| Provided To Others? | Yes |
| Impact | GSK and Imperial college based resarchers are starting or preparing to start clinical studies. |
| Title | Ligand development |
| Description | Lead GSK imaging centre for validation of novel H3, 5HT2, PHNO use and D3 radioligands |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2009 |
| Provided To Others? | Yes |
| Impact | Use of PHNO in dopamine release experiments |
| Description | Cambridge |
| Organisation | Medical Research Council (MRC) |
| Department | MRC Cognition and Brain Sciences Unit |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Imgaging environment, expertise |
| Collaborator Contribution | Staffing, collaborative development of reserach protocols, execution and analysis |
| Impact | Papers, support for case for imaging investment by CBU |
| Description | European FP7 Marie Curie Collaboration |
| Organisation | Julich Research Centre |
| Country | Germany |
| Sector | Public |
| PI Contribution | Constitute phFMRI component of multisite Neurophysics Collaboration |
| Collaborator Contribution | Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints |
| Impact | Multi-disciplinary PhDs in progress |
| Start Year | 2009 |
| Description | European FP7 Marie Curie Collaboration |
| Organisation | Maastricht University (UM) |
| Department | Maastricht School for Mental Health and Neuroscience (MHeNS) |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Constitute phFMRI component of multisite Neurophysics Collaboration |
| Collaborator Contribution | Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints |
| Impact | Multi-disciplinary PhDs in progress |
| Start Year | 2009 |
| Description | European FP7 Marie Curie Collaboration |
| Organisation | University of Oxford |
| Department | Oxford Centre for Functional MRI of the Brain (FMRIB) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Constitute phFMRI component of multisite Neurophysics Collaboration |
| Collaborator Contribution | Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints |
| Impact | Multi-disciplinary PhDs in progress |
| Start Year | 2009 |
| Description | European FP7 Marie Curie Collaboration |
| Organisation | University of Warwick |
| Department | Department of Statistics |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Constitute phFMRI component of multisite Neurophysics Collaboration |
| Collaborator Contribution | Training in use of MRI MTR for outcomes assessment in MS, global statistical analyses for pharmcodynamic endpoints |
| Impact | Multi-disciplinary PhDs in progress |
| Start Year | 2009 |
| Description | FMRIB Centre Oxford |
| Organisation | John Radcliffe Hospital |
| Department | Centre for Functional MRI of the Brain (fMRI) |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Collaborative supervision of fellows and research |
| Collaborator Contribution | Collaborative research, support for fellows and students, research environment |
| Impact | Papers since 2006 with FMRIB coauthors |
| Description | MNI |
| Organisation | McGill University |
| Department | Montreal Neurological Institute and Hospital |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | Staff, patient material, scanning time |
| Collaborator Contribution | Patient recruitment, scanning time, collaborative experimental design and implementation |
| Impact | Multiple papers, commercial support to GSK, gudielines for clinical use of MRI |
| Description | Siena |
| Organisation | University of Siena |
| Department | Neurology Siena |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | Collaborative research design, execution and analysis |
| Collaborator Contribution | Staff, patient material, scanning time |
| Impact | Multiple publications and guidelines for use of clinical MRI |
| Description | Training collaboration |
| Organisation | GE Healthcare Limited |
| Department | Nuclear Medicine |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue. |
| Collaborator Contribution | Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment |
| Impact | None |
| Start Year | 2010 |
| Description | Training collaboration |
| Organisation | Imanova |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue. |
| Collaborator Contribution | Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment |
| Impact | None |
| Start Year | 2010 |
| Description | Training collaboration |
| Organisation | Newcastle University |
| Department | Radiochemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue. |
| Collaborator Contribution | Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment |
| Impact | None |
| Start Year | 2010 |
| Description | Training collaboration |
| Organisation | University of Manchester |
| Department | Wolfson Molecular Imaging Centre (WMIC) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team joined with those from GE Amersham, The Wolfson laboratory at Manchester and Newcastle University to share information on PET radioligand approaches. Direct interactions now have been scheduled to continue. |
| Collaborator Contribution | Advice Joint planning for new radiotracer implementationProvided a training and collaborative environment |
| Impact | None |
| Start Year | 2010 |
| Description | UK Biobank |
| Organisation | UK Biobank |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Expert input as member of steering committee and chair of working group |
| Collaborator Contribution | Organisational structure and expertise |
| Impact | Open access to database 2013 Publications describing Imaging Enhancment Successful funding for imaging enhancement and set up of new centre |
| Start Year | 2008 |
| Title | GlaxoSmithKline Early Development |
| Description | Over last 5 years, research and group have contributed to development of more than 18 different molecules in early development (see letter from Dr. Phil Murphy in 2013 REF submission). Here these contributions all have been "lumped" into a single entry |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Actively seeking support |
| Impact | reducing costs for commercial development, increased competitiveness of UK environment |
| Company Name | Imanova, Ltd. |
| Description | Imanova is a molecular and functional imaging service company. This funding programme further demonstrated the value of public-private partnerships in this area to GSK, who led in formation of the new company. The programme continues to support Imanova and is not providing the latter with a model for training. |
| Year Established | 2011 |
| Impact | Has established proof of principle for training in radiochemistry in the context of this kind of company |
| Website | http://www.imanova.co.uk/ |
| Description | Bard |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Wrote popular book to highlight brain research- "Bard on the Brain". Follow up lectures. Led to creation of Oxford Centre for the Creative Brain Multiple public presentation requests inUK, Europe and US |
| Year(s) Of Engagement Activity | 2006,2009,2015 |
| Description | Head of Div coordination of open day for patients and charities |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Type Of Presentation | Workshop Facilitator |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | Divisional open day attended by about 100 patients, carers, and charity Follow up article in Daily Telegraph on line |
| Year(s) Of Engagement Activity | 2012 |